Dianthus Therapeutics, Inc. (DNTH) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Very low leverage • Severe cash burn Despite an exceptionally strong balance sheet (minimal debt, $51.1M cash, $493.4M tangible equity) DNTH is burning cash with negligible revenue and massive FY2025 operating/free cash losses, leaving its $3.52B market cap deeply disconnected from fundamentals. Valuation: Market cap far outstrips fundamentals—P/S and P/B metrics indicate extreme overvaluation given near-zero revenue and sustained losses.
Price Behavior
Key Price Behavior Insights: • Strong breakout • Resistance-tested • Support cluster Support Level: $78–$82 Resistance Level: $86–$87 DNTH surged from $61.43 to $86.00 in the last month, signaling a strong short-term uptrend but with near-term resistance around $86–$87 and support at $78–$82 that should hold on pullbacks.
Sentiment & News
Key News Insights: • Phase 3 "GO" • $719M financing • Insider selling Dianthus surged on a Phase 3 "GO" readout and a $719M upsized offering but faces mixed signals from insider sales, a Q4 miss and uncertain earnings revisions.
AI Summary
DNTH has shifted from a cash‑constrained biotech to a better‑funded, catalyst‑driven, binary investment—where the upsized financing materially de‑risks liquidity but forces meaningful dilution and makes valuation hinge on Phase‑3/regulatory success and commercialization execution.
Description
Dianthus Therapeutics is a clinical‑stage biotechnology firm developing monoclonal antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, DNTH103, is in Phase 1 clinical trials for generalized myasthenia gravis and several immune‑mediated neuropathies. The company was founded in 2015 and is based in New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 9 | Mar 16 | DNTH | Dianthus Therapeutics, Inc. | Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days. | Closed | -1.6% |